Synergistic disaggregation of platelets by tissue-type plasminogen activator, prostaglandin E1, and nitroglycerin

« Previous Article | Table of Contents | Next Article »

Circulation Research. 1989;65:796-804

This Article

	Full Text (PDF)
	Alert me when this article is cited
	Alert me if a correction is posted
	Citation Map

Services

	Email this article to a friend
	Similar articles in this journal
	Similar articles in PubMed
	Alert me to new issues of the journal
	Download to citation manager
	Request Permissions

Citing Articles

	Citing Articles via HighWire
	Citing Articles via Google Scholar

Google Scholar

	Articles by Stamler, J. S.
	Articles by Loscalzo, J.
	Search for Related Content

PubMed

	PubMed Citation
	Articles by Stamler, J. S.
	Articles by Loscalzo, J.

ARTICLES

Synergistic disaggregation of platelets by tissue-type plasminogen activator, prostaglandin E1, and nitroglycerin

JS Stamler, DE Vaughan and J Loscalzo
Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115.

Endothelial cells produce at least three substances that can attenuate the platelet aggregation response: tissue-type plasminogen activator; the platelet inhibitory prostaglandins I2 and E1; and endothelium- derived relaxing factor, one form of which exhibits properties of nitric oxide. Since platelet aggregates formed in vivo are involved in the initiation of many clinically important occlusive vascular syndromes, we tested the hypothesis that these endothelial products act synergistically to disperse platelet aggregates. Our data reveal that tissue-type plasminogen activator, prostaglandin E1, and nitroglycerin (an organic nitrate activator of guanylate cyclase analogous to endothelium-derived relaxing factor) act synergistically to disaggregate platelets and do so in part by modulation of platelet cyclic nucleotides. These data suggest a potential mechanism by which the endothelium protects against the formation of platelet aggregates in vivo and offer a potential strategy for improving the efficacy of thrombolytic therapy.

This article has been cited by other articles:

E. M. Antman, D. DeMets, and J. Loscalzo
Cyclooxygenase Inhibition and Cardiovascular Risk
Circulation, August 2, 2005; 112(5): 759 - 770.
[Full Text] [PDF]

P. Thanyasiri, D. S. Celermajer, and M. R. Adams
Endothelial dysfunction occurs in peripheral circulation patients with acute and stable coronary artery disease
Am J Physiol Heart Circ Physiol, August 1, 2005; 289(2): H513 - H517.
[Abstract] [Full Text] [PDF]

J.-Y. Qian, A. Haruno, Y. Asada, T. Nishida, Y. Saito, T. Matsuda, and H. Ueno
Local Expression of C-Type Natriuretic Peptide Suppresses Inflammation, Eliminates Shear Stress-Induced Thrombosis, and Prevents Neointima Formation Through Enhanced Nitric Oxide Production in Rabbit Injured Carotid Arteries
Circ. Res., November 29, 2002; 91(11): 1063 - 1069.
[Abstract] [Full Text] [PDF]

D. A. Zvara
Treatment of Perioperative Myocardial Ischemia
Seminars in Cardiothoracic and Vascular Anesthesia, July 1, 2001; 5(2): 166 - 183.
[Abstract] [PDF]

J. Loscalzo
Nitric Oxide Insufficiency, Platelet Activation, and Arterial Thrombosis
Circ. Res., April 27, 2001; 88(8): 756 - 762.
[Abstract] [Full Text] [PDF]

W. F. Baker JR
Thrombosis and Hemostasis in Cardiology: Review of Pathophysiology and Clinical Practice (Part I)
Clinical and Applied Thrombosis/Hemostasis, January 1, 1998; 4(1): 51 - 75.
[Abstract] [PDF]

S.-K. Yao, S. Akhtar, T. Scott-Burden, J. C. Ober, P. Golino, L. M. Buja, W. Casscells, and J. T. Willerson
Endogenous and Exogenous Nitric Oxide Protect Against Intracoronary Thrombosis and Reocclusion After Thrombolysis
Circulation, August 15, 1995; 92(4): 1005 - 1010.
[Abstract] [Full Text]

				P. Thanyasiri, D. S. Celermajer, and M. R. Adams Endothelial dysfunction occurs in peripheral circulation patients with acute and stable coronary artery disease Am J Physiol Heart Circ Physiol, August 1, 2005; 289(2): H513 - H517. [Abstract] [Full Text] [PDF]

				J.-Y. Qian, A. Haruno, Y. Asada, T. Nishida, Y. Saito, T. Matsuda, and H. Ueno Local Expression of C-Type Natriuretic Peptide Suppresses Inflammation, Eliminates Shear Stress-Induced Thrombosis, and Prevents Neointima Formation Through Enhanced Nitric Oxide Production in Rabbit Injured Carotid Arteries Circ. Res., November 29, 2002; 91(11): 1063 - 1069. [Abstract] [Full Text] [PDF]

				D. A. Zvara Treatment of Perioperative Myocardial Ischemia Seminars in Cardiothoracic and Vascular Anesthesia, July 1, 2001; 5(2): 166 - 183. [Abstract] [PDF]

				J. Loscalzo Nitric Oxide Insufficiency, Platelet Activation, and Arterial Thrombosis Circ. Res., April 27, 2001; 88(8): 756 - 762. [Abstract] [Full Text] [PDF]

				W. F. Baker JR Thrombosis and Hemostasis in Cardiology: Review of Pathophysiology and Clinical Practice (Part I) Clinical and Applied Thrombosis/Hemostasis, January 1, 1998; 4(1): 51 - 75. [Abstract] [PDF]

				S.-K. Yao, S. Akhtar, T. Scott-Burden, J. C. Ober, P. Golino, L. M. Buja, W. Casscells, and J. T. Willerson Endogenous and Exogenous Nitric Oxide Protect Against Intracoronary Thrombosis and Reocclusion After Thrombolysis Circulation, August 15, 1995; 92(4): 1005 - 1010. [Abstract] [Full Text]